FDA 483 - Tanvex BioPharma USA, Inc - January 24, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Tanvex BioPharma USA, Inc. in San Diego, CA, revealed significant deficiencies in cGMP procedures and records, quality oversight, and facility and equipment maintenance. Observations included inadequate labeling for storage conditions, inaccurate batch records, and failure to follow production procedures. Additionally, the firm lacked proper trending for its pest control program, failed to qualify a cGMP storage room, and exhibited poor microbial control and cleanliness in manufacturing areas.
ID · a9d30f1e-d696-45b8-b908-bd03a01a3ccb